Advancing Type 2 Diabetes Care With Modern Insulins
Goals
Type 2 Diabetes Is Progressive
Most Patients Are Not Achieving HbA1C < 7%
DCCT Results: HbA1c and Relative Risk of Diabetic Complicationsa,b
By the Time of Diagnosis, β-Cell Decline Exceeds 50%
Most Patients With T2D Will Eventually Need Insulin
Basal Insulin Therapy in T2D
Basal Insulin Improves Glycemic Control
Basal Insulin Replacement Therapy
Currently Available Basal Insulins
Time-action Profiles Illustrate Variability
Limitations of Current Basal Insulins
How Often Does Hypoglycemia Occur?
When Does Hypoglycemia Occur?
Hypoglycemia Is Associated With ECG Abnormalities
Cost of Hypoglycemia
Insulin Analogs Are Associated With Lower Rates of
Hypoglycemia
In Search of Improved Pharmacokinetic/Pharmacodyna
mic Profiles
Why We Need Better Basal Insulins
Novel Basal Insulins on the Horizon
Desired Properties for A Basal Insulin Product Relative to Existing
Therapy
Similar Outcomes With Flexible and Fixed Once-Daily Degludec*
Dosing
Pegylated Lispro* vs Glargine in Adults With T2D at 12 Weeks
Investigational New Insulin Glargine U300 (300 U/mL, Gla-
300)
Glargine U300
Benefits of Newer Basal Insulins
Take-home Messages
Abbreviations
Abbreviations (cont)
References
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)